New non-opioid analgesic generation drug with anti-inflammatory effect, API

COOPERATION OPTIONS 

LICENSE

FROM 200 MILLION RUR

RESEARCH PARTNERSHIP

FROM 50 MILLION RUR

more detail

ABOUT THE PROJECT

Neuronal Acid-Sensitive Receptor ASICs Antagonist, API

NEW NON-OPIOID ANALGESIC GENERATION DRUG WITH ANTI-INFLAMMATORY EFFECT

A plant lignin, originally derived from the medicinal plant Thymus (Thýmus armeniacus), has no analogues on the market by its action and chemical formula, has both anti-pain and anti-inflammatory properties and can be obtained by chemical synthesis, which makes it extremely promising for implementation.

Stage of development

NEW NON-OPIOID ANALGESIC GENERATION DRUG WITH ANTI-INFLAMMATORY EFFECT, API

COOPERATION OPTIONS 

LICENSE

FROM 200 MILLION RUR

RESEARCH PARTNERSHIP

FROM 50 MILLION RUR

more detail

ABOUT THE PROJECT

NEURONAL ACID-SENSITIVE RECEPTOR ASICS ANTAGONIST, API

NEW NON-OPIOID ANALGESIC GENERATION DRUG WITH ANTI-INFLAMMATORY EFFECT

A plant lignin, originally derived from the medicinal plant Thymus (Thýmus armeniacus), has no analogues on the market by its action and chemical formula, has both anti-pain and anti-inflammatory properties and can be obtained by chemical synthesis, which makes it extremely promising for implementation.

Stage of development

STAGE OF DEVELOPMENT
& RESULTS OF INTELLECTUAL ACTIVITY STATUS


EFFECT

The resulting substance belongs to the class of lignans - is an antagonist of the two most important types of acid-sensitive receptors: ASIC1a and ASIC3, gives a pronounced anti-pain and anti-inflammatory effect in animals and is positioned as a drug for acute and chronic pain as a non-opioid class analgesic.

Description: light beige powder for solution preparation for intravenous/intramuscular injection or for preparation of intranasal dosage forms.

APPLICATION

The main application of this substance as an ASIC1a/ASIC3 inhibitor is as an APS for drug creation to relieve inflammation, visceral pain, skin irritations and any peripheral and central nervous system disorders (neuropathies).

BENEFITS

A wide range of application methods (parenteral, intranasal)
HIGH EFFECTIVENESS COMPARING WITH MODERN NSAIDS
ABSENCE OF SIDE EFFECTS TYPICAL FOR NSAIDS (NO NEGATIVE EFFECTS ON THE GASTROINTESTINAL TRACT AND VASCULAR SYSTEM)
ABSENCE OF ADDICTIVE AND SEDATIVE EFFECTS
LOW LEVEL OF TOXICITY 

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - from RUB 100 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 401 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:


• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

• Start manufacturing
Starting at 51 million RUR

• Promotion activities
Starting at 50 million RUR

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

HEAD OF THE PROJECT

SERGEY KOZLOV

Dr. of Sc.

Head of the Laboratory of Neuroreceptors and Neuroregulators

 


PUBLICATIONS

Lignan from thyme possesses inhibitory effect on ASIC3 channel current. Journal of Biological Chemistry, 287, 39, 32993-33000, 2012

Dubinnyi, Maxim A; Osmakov, Dmitry I; Koshelev, Sergey G; Kozlov, Sergey A; Andreev, Yaroslav A; Zakaryan, Naira A; Dyachenko, Igor A; Bondarenko, Dmitry A; Arseniev, Alexander S; Grishin, Eugene V

Biological activity of sevanol and its analogues. Russian Journal of Bioorganic Chemistry, 41, 5, 543-547, 2015

Osmakov, DI; Koshelev, SG; Belozerova, OA; Kublitski, VS; Andreev, Ya A; Grishin, EV; Kozlov, SA

Analgesic Activity of Acid-Sensing Ion Channel 3 (ASIС3) Inhibitors: Sea Anemones Peptides Ugr9-1 and APETx2 versus Low Molecular Weight Compounds. Marine drugs, 16, 12, 500, 2018

Andreev, Yaroslav A; Osmakov, Dmitry I; Koshelev, Sergey G; Maleeva, Ekaterina E; Logashina, Yulia A; Palikov, Victor A; Palikova, Yulia A; Dyachenko, Igor A; Kozlov, Sergey A

Sevanol and its analogues: chemical synthesis, biological effects and molecular docking. Pharmaceuticals, 13, 8, 163, 2020

Belozerova, Olga A; Osmakov, Dmitry I; Vladimirov, Andrey; Koshelev, Sergey G; Chugunov, Anton O; Andreev, Yaroslav A; Palikov, Victor A; Palikova, Yulia A; Shaykhutdinova, Elvira R; Gvozd, Artem N

CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more
Report abuse